医学
肺癌筛查
肺癌
阶段(地层学)
癌症
内科学
荟萃分析
生物
古生物学
作者
Yanju Li,Yihui Du,Yubei Huang,Yingru Zhao,Grigory Sidorenkov,Marleen Vonder,Xiaonan Cui,Shuxuan Fan,Monique D. Dorrius,Rozemarijn Vliegenthart,Harry J.M. Groen,Shiyuan Liu,Fengju Song,Kexin Chen,Geertruida H. de Bock,Zhaoxiang Ye
标识
DOI:10.1016/j.ejrad.2021.109988
摘要
Objective To evaluate the efficiency of low-dose computed tomography (LDCT) screening for lung cancer in China by analyzing the baseline results of a community-based screening study accompanied with a meta-analysis. Methods A first round of community-based lung cancer screening with LDCT was conducted in Tianjin, China, and a systematic literature search was performed to identify LDCT screening and registry-based clinical studies for lung cancer in China. Baseline results in the community-based screening study were described by participant risk level and the lung cancer detection rate was compared with the pooled rate among the screening studies. The percentage of patients per stage was compared between the community-based study and screening and clinical studies. Results In the community-based study, 5523 participants (43.6% men) underwent LDCT. The lung cancer detection rate was 0.5% (high-risk, 1.2%; low-risk, 0.4%), with stage I disease present in 70.0% (high-risk, 50.0%; low-risk, 83.3%), and the adenocarcinoma present in 84.4% (high-risk, 61.5%; low-risk, 100%). Among all screen-detected lung cancer, women accounted for 8.3% and 66.7% in the high- and low-risk group, respectively. In the screening studies from mainland China, the lung cancer detection rate 0.6% (95 %CI: 0.3%–0.9%) for high-risk populations. The proportions with carcinoma in situ and stage I disease in the screening and clinical studies were 76.4% (95 %CI: 66.3%–85.3%) and 15.2% (95 %CI: 11.8%–18.9%), respectively. Conclusions The stage shift of lung cancer due to screening suggests a potential effectiveness of LDCT screening in China. Nearly 70% of screen-detected lung cancers in low-risk populations are identified in women.
科研通智能强力驱动
Strongly Powered by AbleSci AI